{"id":31503,"date":"2025-05-08T00:47:04","date_gmt":"2025-05-07T22:47:04","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/05\/08\/pgi2-restricts-trained-ilc2-responses-in-allergic-inflammation\/"},"modified":"2025-05-08T00:47:04","modified_gmt":"2025-05-07T22:47:04","slug":"pgi2-restricts-trained-ilc2-responses-in-allergic-inflammation","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/05\/08\/pgi2-restricts-trained-ilc2-responses-in-allergic-inflammation\/","title":{"rendered":"PGI2 restricts trained ILC2 responses in allergic inflammation"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2025 May 7:vkaf088. doi: 10.1093\/jimmun\/vkaf088. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Pulmonary type 2 innate lymphoid cells (ILC2s) exhibit immune memory, termed &#8220;trained immunity,&#8221; which enhances their activation following exposure to an independent protease-containing allergen. The role of prostaglandin I2 (PGI2), a cyclooxygenase (COX) pathway metabolite, in modulating these trained ILC2 responses remains unclear. PGI2 acts through its G protein-coupled receptor IP. We hypothesized that IP signaling inhibits ILC2 training. To test this hypothesis, we used a mouse ILC2 training model in which we challenged wild-type (WT) and IP knockout (KO) mice with Alternaria alternata extract (Alt) to induce ILC2 activation and training. After a 33-d resting period, ILC2 responses subsided to a homeostatic level. Mice were then intranasally challenged with papain to evaluate responses to an unrelated allergen. IP KO mice displayed significantly heightened ILC2 interleukin (IL)-13 expression and with concomitant increased eosinophilia in the lungs post-papain challenge compared with WT control mice. Notably, neither WT nor IP KO mice challenged with papain only, devoid of ILC2 training, exhibited lung type 2 responses. The augmented type 2 inflammation observed in IP KO mice following both Alt and papain challenges correlated with increased numbers and percentages of IL-13-producing ILC2s and greater mean fluorescence intensity of IL-13 compared with WT mice. Furthermore, RNA sequencing of sorted ILC2s from WT and IP KO mice following Alt-papain challenges revealed heightened activation of immune response pathways and mitochondrial respiratory pathways in IP-deficient ILC2s. These findings reveal an inhibitory role of PGI2 signaling in trained ILC2 responses, emphasizing its pivotal contribution to innate immune responses and allergic inflammation.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40334085\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20250507184657&amp;v=2.18.0.post9+e462414\">40334085<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkaf088\">10.1093\/jimmun\/vkaf088<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2025 May 7:vkaf088. doi: 10.1093\/jimmun\/vkaf088. Online ahead of print. ABSTRACT Pulmonary type 2 innate lymphoid cells (ILC2s) exhibit immune memory, termed &#8220;trained immunity,&#8221; which enhances their activation following exposure to an independent protease-containing allergen. The role of prostaglandin I2 (PGI2), a cyclooxygenase (COX) pathway metabolite, in modulating these trained ILC2 responses remains unclear. &#8230; <a title=\"PGI2 restricts trained ILC2 responses in allergic inflammation\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/05\/08\/pgi2-restricts-trained-ilc2-responses-in-allergic-inflammation\/\" aria-label=\"Read more about PGI2 restricts trained ILC2 responses in allergic inflammation\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-31503","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/31503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=31503"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/31503\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=31503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=31503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=31503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}